Affinage

BCAT1

Branched-chain-amino-acid aminotransferase, cytosolic · UniProt P54687

Length
386 aa
Mass
43.0 kDa
Annotated
2026-06-09
100 papers in source corpus 36 papers cited in narrative 36 extracted findings
Cross-family judge vs UniProt: UniProt preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

BCAT1 (BCATc) is a cytosolic branched-chain amino acid transaminase that initiates BCAA catabolism by transferring amino groups from BCAAs to α-ketoglutarate (αKG), thereby consuming αKG, generating glutamate and branched-chain α-keto acids (BCKAs), and serving as a central regulator of intracellular αKG homeostasis across cancer and immune contexts (PMID:23793099, PMID:29144447). By depleting αKG, BCAT1 restrains αKG-dependent dioxygenases—reducing TET activity to cause DNA hypermethylation that mimics IDH mutation (PMID:29144447), impairing KDM histone demethylases to elevate H3K9me3 and suppress ATM-dependent DNA repair (PMID:38340163), and reciprocally driving promoter H3K4me3 at inflammatory genes (PMID:40530920)—and stabilizing HIF1α by limiting EGLN1 activity (PMID:29144447). Its catabolic products feed anabolic signaling: BCKA and leucine sustain mitochondrial metabolism, nucleotide biosynthesis, and mTORC1 activity, with αKG supplementation producing synthetic lethality in BCAT1-null glioblastoma (PMID:35499760, PMID:24847056). BCAT1 also exerts catalysis-independent functions through a conserved CXXC redox motif that metabolizes H2O2, buffers ROS, and—during mitosis—promotes Aurora kinase B localization to centromeres to maintain chromosome segregation fidelity (PMID:36260995, PMID:35453368). Beyond transamination, BCAT1 directly binds RhoC to elevate its GTPase activity, an interaction reinforced by BCKA binding to RhoC, thereby promoting cell motility (PMID:37337119). BCAT1 expression is driven transcriptionally by c-Myc and NOTCH1 promoter binding and by DOT1L-mediated H3K79 methylation (PMID:23758864, PMID:39234857, PMID:26783998), while its protein stability is controlled by BCKDK phosphorylation and SIRT5 desuccinylation that antagonize STUB1/CHIP-mediated K48 ubiquitination and proteasomal degradation (PMID:38621458, PMID:39075053, PMID:40195331). Through these axes BCAT1 supports proliferation, stemness, and therapy resistance in multiple cancers, lymphocyte and osteoclast function, and is induced in neurons and astrocytes consistent with a role in glutamate metabolism (PMID:15329886, PMID:15233768, PMID:39234857, PMID:40924473).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 1999 Medium

    Established that BCAT1 metabolic products themselves can drive cell fate, showing that a keto-acid product of leucine catabolism induces apoptosis.

    Evidence Bcat1/Eca39 overexpression in murine cells under serum deprivation with α-ketoisocaproate treatment

    PMID:10471790

    Open questions at the time
    • Mechanism linking keto-acid to apoptotic machinery not defined
    • Single overexpression system without endogenous validation
  2. 2004 Medium

    Defined the in vivo expression pattern of BCATc in neural tissue, linking it to glutamate metabolism in distinct neuronal and astrocytic compartments.

    Evidence Immunohistochemistry across rat brain regions; mRNA fingerprinting and in situ hybridization in a BDNF-treated visual cortex lesion model

    PMID:15233768 PMID:15329886

    Open questions at the time
    • Functional consequence of neuronal vs astrocytic localization not tested
    • No direct measurement of neurotransmitter pools
  3. 2013 High

    Identified BCAT1 as a driver of BCAA catabolism and glutamate excretion in glioma and showed its expression is governed by αKG availability and antagonized by mutant IDH1, linking it to the IDH oncometabolite axis; concurrently established c-Myc as a direct transcriptional activator.

    Evidence shRNA knockdown and xenografts in glioma; ectopic mutant IDH1 in astrocytes; ChIP and luciferase reporter for c-Myc on the BCAT1 promoter

    PMID:23758864 PMID:23793099

    Open questions at the time
    • Direct epigenetic consequences of αKG depletion not yet measured here
    • Mechanism by which IDH1 mutation suppresses BCAT1 not resolved
  4. 2014 High

    Connected BCAT1 to immune signaling by showing TCR-induced BCATc lowers intracellular leucine to restrain mTORC1 and glycolysis in CD4+ T cells, with NFAT placed upstream.

    Evidence BCATc knockout mouse, leucine transamination assays, mTORC1 phospho-readouts, cyclosporin A inhibition

    PMID:24847056

    Open questions at the time
    • Whether leucine depletion is the sole mTORC1-limiting mechanism unclear
    • Context-dependence relative to anabolic roles in cancer not reconciled
  5. 2017 High

    Established the core mechanistic principle that BCAT1 controls intracellular αKG to govern HIF1α stability and TET-dependent DNA methylation, mimicking IDH mutation, and links BCAA catabolism to mitochondrial biogenesis via mTOR.

    Evidence BCAT1 gain/loss in leukemia cells with metabolomics, HIF1α/TET assays, DNA methylation profiling; breast cancer mTOR/AMPK/SIRT1 analysis

    PMID:28235484 PMID:29144447

    Open questions at the time
    • Generality of αKG-mediated epigenetic effects across tissues not yet shown
    • mTOR activation mechanism (metabolite vs other) not fully defined
  6. 2016 Medium

    Identified epigenetic transcriptional control of BCAT1 via DOT1L-mediated H3K79 methylation in breast cancer.

    Evidence DOT1L knockdown/overexpression, H3K79me ChIP at BCAT1 locus, sphere/migration assays

    PMID:26783998

    Open questions at the time
    • Direct vs indirect DOT1L effect on BCAT1 not separated
    • Single lineage context
  7. 2020 Medium

    Expanded BCAT1 regulation to additional transcriptional and post-transcriptional inputs and to stromal supply roles, showing TGF-β/SMAD5 control in fibroblasts and an RNA-binding/ER-stress axis driving autophagy.

    Evidence TGF-β/SMAD5 perturbation and isotope tracing in CAFs; ZNF423–BCAT1 mRNA pulldown and BCAT1–IRE1 Co-IP in hypoxic PASMCs

    PMID:32694827 PMID:32938905

    Open questions at the time
    • Direct SMAD5 binding to BCAT1 not shown
    • Non-metabolic IRE1 interaction lacks structural detail
  8. 2021 Medium

    Broadened BCAT1's downstream signaling outputs and physiological roles, linking it to mTOR-driven autophagy and chemoresistance, PI3K/AKT and Ras/ERK signaling, SOX2-dependent stemness, and enzyme-dependent osteoclast maturation.

    Evidence Knockdown/overexpression with pathway Western blots and inhibitors (LY294002, chloroquine), αKG/SOX2 quantification, catalytic-dead BCAT1 mutants and gabapentin in osteoclast/muscle systems, in vivo models

    PMID:32523652 PMID:33568627 PMID:34164393 PMID:34646394 PMID:35760874

    Open questions at the time
    • Whether mTOR/PI3K effects are direct or metabolite-driven not always resolved
    • Tissue-specific reconciliation of pro- vs anti-mTOR effects pending
  9. 2022 High

    Revealed catalysis-independent functions of BCAT1, defining the CXXC redox motif as a peroxide-metabolizing antioxidant module that controls mitotic Aurora B localization and chromosome segregation, and demonstrating αKG synthetic lethality and αKG-dependent epigenetic/DNA-repair control.

    Evidence CXXC separation-of-function rescue with live imaging and sulfenylation assays; in vitro H2O2 metabolism with purified protein; metabolic synthetic-lethal screens with BCKA/αKG rescue; H3K9me3/ATM/PARP-inhibitor analyses

    PMID:35453368 PMID:35499760 PMID:35562710 PMID:36260995 PMID:38340163

    Open questions at the time
    • Molecular basis of BCAT1–Aurora B coupling unknown
    • How redox and metabolic functions are partitioned in vivo unresolved
  10. 2023 High

    Demonstrated a direct non-metabolic protein interaction by which BCAT1 binds RhoC to elevate its GTPase activity, with BCKA acting as a direct RhoC ligand, and identified a gain-of-function mutation enhancing this axis.

    Evidence Co-IP, RhoC GTPase and BCKA-RhoC binding assays, BCAT1 E61A mutant and KO rescue, in vivo metastasis model

    PMID:37337119

    Open questions at the time
    • Structural interface of BCAT1–RhoC binding not defined
    • Reciprocal validation of interaction in additional systems limited
  11. 2024 Medium

    Mapped the post-translational and transcriptional control network stabilizing BCAT1—BCKDK phosphorylation and STUB1/CHIP ubiquitination at defined sites—and added NOTCH1, TFEB, PBX3, HuR, and CREB-linked inputs while detailing metabolite-driven immune and leukemic phenotypes.

    Evidence Phospho/ubiquitin site mapping and Co-IP for BCKDK–STUB1–BCAT1; ChIP for NOTCH1; TFEB/PBX3/HuR perturbations with RIP and metabolomics; metabolite tracing to 3-HB and HMB with EAE, AML, CML, and B-cell/lymphoma models

    PMID:36418376 PMID:38369471 PMID:38621458 PMID:38938061 PMID:39075053 PMID:39085353 PMID:39234857 PMID:39412615 PMID:39455853

    Open questions at the time
    • Hierarchy and cross-talk among multiple regulators not integrated
    • Several transcriptional links lack direct promoter-binding evidence
  12. 2025 Medium

    Linked subcellular localization and an additional PTM to BCAT1 function, showing lysosomal-membrane localization supporting BCAA synthesis and mTORC1 in B cells, SIRT5 desuccinylation at K39 stabilizing BCAT1 against CHIP degradation, and Plk4 phosphorylation negatively regulating its αKG-dependent epigenetic activity.

    Evidence Multiomics and immunofluorescence in primary B cells; SIRT5 knockdown with K39 desuccinylation mapping and CHIP Co-IP; Plk4 phospho-Thr333 mapping with ChIP and αKG metabolomics in Müller cells

    PMID:40195331 PMID:40530920 PMID:40924473

    Open questions at the time
    • Mechanism of lysosomal recruitment unknown
    • Interplay between SIRT5, BCKDK, and CHIP on the same protein not jointly tested

Open questions

Synthesis pass · forward-looking unresolved questions
  • How BCAT1's metabolic, redox/CXXC, and direct protein-interaction (RhoC, Aurora B, IRE1) functions are coordinated and partitioned within a cell, and what determines its divergent mTORC1 outcomes across cell types, remains unresolved.
  • No structural model integrating catalytic and non-catalytic domains
  • Spatial coordination of cytosolic, lysosomal, and mitotic pools undefined
  • Context determinants of pro- vs anti-mTORC1 activity unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 5 GO:0016209 antioxidant activity 1 GO:0098772 molecular function regulator activity 1
Localization
GO:0005829 cytosol 2 GO:0005694 chromosome 1 GO:0005764 lysosome 1
Pathway
R-HSA-1430728 Metabolism 3 R-HSA-162582 Signal Transduction 3 R-HSA-168256 Immune System 3 R-HSA-392499 Metabolism of proteins 3 R-HSA-4839726 Chromatin organization 3 R-HSA-1640170 Cell Cycle 1
Partners
BCKDKHURIRE1PLK4RHOCSIRT5STUB1ZNF423

Evidence

Reading pass · 36 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2013 BCAT1 initiates catabolism of branched-chain amino acids (BCAAs) in glioblastoma; suppression of BCAT1 in glioma cell lines blocked glutamate excretion and reduced proliferation and invasiveness in vitro, and decreased tumor growth in xenograft models. BCAT1 expression was dependent on α-ketoglutarate substrate concentration and could be suppressed by ectopic overexpression of mutant IDH1 in immortalized human astrocytes, linking IDH1 function to BCAT1 expression. shRNA knockdown in glioma cell lines, xenograft mouse model, ectopic mutant IDH1 overexpression in astrocytes, glutamate excretion assay Nature medicine High 23793099
2017 BCAT1 is a critical regulator of intracellular α-ketoglutarate (αKG) homeostasis in AML stem cells: it transfers α-amino groups from BCAAs to αKG, consuming αKG. Knockdown of BCAT1 caused αKG accumulation, leading to EGLN1-mediated HIF1α protein degradation and growth/survival defects. Overexpression of BCAT1 decreased intracellular αKG and caused DNA hypermethylation through reduced TET enzyme activity, mimicking IDH mutation effects. BCAT1 knockdown and overexpression in leukemia cells, high-resolution proteomics, intracellular metabolite measurements (αKG), HIF1α protein level analysis, TET activity assay, DNA methylation profiling Nature High 29144447
2017 BCAT1 promotes mitochondrial biogenesis, ATP production, and represses mitochondrial ROS in breast cancer cells by activating mTOR (but not AMPK or SIRT1) signaling. Knockdown of BCAT1 repressed cell growth and colony formation. BCAT1 knockdown and overexpression in breast cancer cells, mTOR/AMPK/SIRT1 pathway Western blot, mitochondrial biogenesis and ATP assays Biochemical and biophysical research communications Medium 28235484
2014 TCR activation of CD4+ T cells triggers expression of cytosolic BCATc (BCAT1), which increases leucine transamination and lowers intracellular leucine. BCATc(-/-) T cells have higher intracellular leucine, elevated mTORC1 activation (increased phospho-S6 and 4EBP-1), and higher glycolytic rates than wild-type T cells. BCATc induction by TCR is blocked by the calcineurin/NFAT inhibitor cyclosporin A, placing NFAT upstream of BCAT1 expression. BCATc knockout mouse (BCATc-/-), leucine transamination assays, mTORC1 phosphorylation (S6, 4EBP-1) by Western blot, glycolysis measurements, cyclosporin A pharmacological inhibition The Journal of biological chemistry High 24847056
2013 c-Myc directly binds to the c-Myc binding site in the BCAT1 promoter and upregulates BCAT1 expression in nasopharyngeal carcinoma (NPC). Knockdown of c-Myc downregulates BCAT1, and BCAT1 knockdown reduces NPC cell proliferation, migration, and invasion. ChIP assay (c-Myc binding to BCAT1 promoter), luciferase reporter assay, c-Myc siRNA knockdown, BCAT1 siRNA knockdown, colony formation, migration and invasion assays Molecular cancer High 23758864
2020 In pancreatic cancer stroma, TGF-β–SMAD5 axis directly targets BCAT1 in cancer-associated fibroblasts (CAFs), dictating internalization of extracellular matrix to supply amino-acid precursors for BCKA secretion, which is then utilized by adjacent cancer cells. TGF-β–SMAD5 pathway perturbation in CAFs, BCAT1 expression measurement, metabolic flux analysis (isotope tracing), circulating tumor cells and PDAC tissue slice validation Nature metabolism Medium 32694827
2004 BCATc (BCAT1) is expressed exclusively in neurons in the adult rat brain. In glutamatergic neurons (e.g., granule cells of cerebellum and dentate gyrus), BCATc localizes to axons and nerve terminals; in GABAergic neurons (Purkinje cells, hippocampal pyramidal basket cells), it is concentrated in cell bodies. BCATc is strongly expressed in the mossy fiber pathway. This localization supports a role in modulating glutamate availability for neurotransmitter release or GABA synthesis. Immunohistochemistry in rat brain sections, cell-type specific localization in neuronal subtypes The Journal of comparative neurology Medium 15329886
2022 BCAT1 localizes to mitotic structures and has a non-metabolic function as a mitotic regulator. The BCAT1 CXXC redox motif controls cysteine sulfenylation specifically in mitotic cells, promotes Aurora kinase B localization to centromeres, and is required for accurate chromosome segregation in cancer and iPSC cells. Loss of BCAT1 causes mitotic errors; rescue requires the intact CXXC motif, not catalytic BCAA transaminase activity. Gene knockout and rescue with CXXC mutant vs. wild-type BCAT1, live-cell imaging of mitotic structures, immunofluorescence of Aurora B at centromeres, cysteine sulfenylation assay, human cerebral organoid and mouse syngraft tumor models Cell reports High 36260995
2022 The BCAT1 CXXC motif can metabolize H2O2 in vitro (novel antioxidant activity), whereas CXXC-mutant BCAT1 or wild-type BCAT2 cannot. In AML cells, overexpression of wild-type BCAT1 reduces intracellular ROS compared to CXXS mutant, reduces myeloid differentiation markers, and protects against apoptosis, implicating the BCAT1 CXXC motif in redox buffering and myeloid differentiation block. In vitro H2O2 metabolism assay with purified BCAT1 protein (WT vs. CXXC mutant), intracellular ROS measurement in U937 AML cells, flow cytometry for myeloid markers and apoptosis Antioxidants (Basel, Switzerland) High 35453368
2023 BCAT1 directly interacts with RhoC (identified by co-IP/pulldown), leading to elevation of RhoC GTPase activity. Additionally, the BCAA-derived metabolite branched-chain α-keto acid (BCKA) directly binds to RhoC and promotes its activity. A gain-of-function BCAT1 E61A mutation (enriched in gastric cancer) confers higher enzymatic activity, boosting BCAA catabolism, cell motility, and tumor development. BCAT1 KO-suppressed cell motility is rescued by BCAT1E61A expression or BCKA supplementation. Co-immunoprecipitation (BCAT1–RhoC interaction), RhoC GTPase activity assay, BCKA-RhoC direct binding assay, BCAT1 E61A mutant expression, BCAT1 knockout rescue experiments, in vitro motility assays, in vivo peritoneal metastasis model Nature metabolism High 37337119
2022 Loss of BCAT1 in IDH-wildtype GBM cells increases NAD+/NADH ratio but impairs oxidative phosphorylation, mTORC1 activity, and nucleotide biosynthesis. Supplementing αKG in BCAT1-loss cells causes synthetic lethality (not seen with loss of BCAT2, BCKDHA, or GPT2). Synthetic lethality is prevented by supplementation with BCKA (downstream BCAT1 products), placing BCAT1 in the pathway supplying BCKA for mitochondrial metabolism and biosynthesis. Metabolic synthetic lethal screen, BCAT1 KO in patient-derived GBM cells, BCKA supplementation rescue, NAD+/NADH ratio measurement, mTORC1 activity assay, nucleotide quantification, in vivo xenograft model with gabapentin + αKG cotreatment Cancer research High 35499760
2021 BCAT1 enzymatic activity is required for osteoclast maturation: selective inhibition with gabapentin or expression of enzymatically dead BCAT1 (active-site mutant) abrogated RANKL-induced osteoclast differentiation. Valine was the most critical BCAA for osteoclast maturation, and BCAT1 activity sustains BCAA catabolism needed for this process. Gabapentin pharmacological inhibition, enzymatically dead BCAT1 mutant expression, RANKL-induced osteoclast differentiation assay, BCAA supplementation/depletion, in vivo LPS-induced calvarial bone loss model Experimental & molecular medicine Medium 35760874
2020 BCAT1 binds the RNA-binding protein ZNF423 via AU-rich elements in the BCAT1 mRNA 3'-UTR (posttranscriptional regulation). BCAT1 protein then binds IRE1 on the ER to activate the IRE1–XBP-1–RIDD axis, leading to upregulation of BECN1 and Atg5 and autophagy activation in hypoxic pulmonary artery smooth muscle cells. RNA binding protein pulldown (ZNF423–BCAT1 mRNA), Co-IP (BCAT1–IRE1), BECN1/Atg5 protein expression assays, autophagy flux analysis in hypoxic PASMCs and rat model Cell death & disease Medium 32938905
2024 BCKDK (branched chain ketoacid dehydrogenase kinase) phosphorylates BCAT1 at S5, S9, and T312, increasing its catalytic and antioxidant activity and stability. STUB1 (CHIP) is the E3 ubiquitin ligase for BCAT1, ubiquitinating it for proteasomal degradation. BCKDK also phosphorylates STUB1 at S19, which disrupts the STUB1–BCAT1 interaction and inhibits BCAT1 ubiquitin-mediated degradation. This BCKDK–STUB1–BCAT1 cross-talk promotes GBM proliferation and temozolomide resistance. Phosphorylation site mapping (S5/S9/T312), BCKDK kinase assay, Co-IP (STUB1–BCAT1 interaction), ubiquitination assay (K48-linkage), STUB1 site mutants, in vivo and in vitro proliferation assays, temozolomide sensitivity assay Cancer letters Medium 38621458
2024 CHIP (STUB1) acts as an E3 ubiquitin ligase for BCAT1, interacting via its coiled-coil domain with BCAT1 to promote K48-linkage ubiquitin degradation via the proteasome at Lys360. CHIP-mediated BCAT1 degradation induces metabolic reprogramming, reduces glutathione (GSH) synthesis, increases oxidative stress, and sensitizes glioma cells to temozolomide. Co-IP (CHIP–BCAT1), ubiquitination site mapping (Lys360), domain mapping (CHIP coiled-coil), proteasome inhibitor rescue, in vitro and in vivo tumor growth, GSH quantification Cell death & disease Medium 39075053
2025 SIRT5-mediated desuccinylation of BCAT1 at K39 inhibits BCAT1's interaction with the E3 ubiquitin ligase CHIP, preventing BCAT1 proteasomal degradation. BCAT1 stabilization by SIRT5 promotes glioma cell proliferation and ferroptosis resistance. BCAT1 overexpression rescues the proliferation inhibition and ferroptosis sensitivity caused by SIRT5 knockdown. SIRT5 knockdown, desuccinylation site mapping (K39), Co-IP (BCAT1–CHIP interaction), ubiquitin-proteasome degradation assay, BCAT1 overexpression rescue, ferroptosis assays, proteomic and metabolomic analyses Cell death & disease Medium 40195331
2016 DOT1L histone methyltransferase regulates BCAT1 expression through H3K79 methylation at the BCAT1 locus in breast cancer cells. BCAT1 was identified as a DOT1L target gene responsible for DOT1L-mediated sphere formation and cell migration. DOT1L knockdown and overexpression, H3K79 methylation ChIP at BCAT1 locus, BCAT1 expression analysis, sphere formation and migration assays Biochimie Medium 26783998
2021 BCAT1 depletion of αKG in lung cancer cells promotes expression of SOX2, a transcription factor regulating cancer cell stemness and metastasis. shRNA-mediated BCAT1 knockdown reduced αKG levels, increased SOX2 expression, reduced cell migration in vitro, and inhibited metastasis to distal organs in nude mice. shRNA knockdown of BCAT1, αKG quantification, SOX2 protein/mRNA measurement, in vitro migration assay, in vivo lung metastasis mouse model Theranostics Medium 34646394
2021 BCAT1 decreases cisplatin sensitivity in cancer cells by inducing mTOR-mediated autophagy. Cisplatin upregulates BCAT1 expression; BCAT1 knockdown or leucine supplementation activates mTOR, inhibits autophagy, and increases cisplatin sensitivity. Chloroquine (autophagy inhibitor) phenocopies BCAT1 knockdown in vivo. BCAT1 knockdown, leucine/BCAA supplementation, mTOR signaling by Western blot, autophagy flux assays (LC3, p62), cisplatin sensitivity assays in vitro and in vivo, chloroquine inhibitor comparison Cell death & disease Medium 33568627
2024 BCAT1-mediated BCAA catabolism generates leucine and other BCAAs that sustain SHOC2 (a leucine-rich repeat protein) expression, thereby maintaining the SHOC2-RAS-ERK signaling pathway and TNBC cell survival. Eupalinolide B (EB) directly binds and inhibits BCAT1 (confirmed by ABPP, pull-down, CETSA, MST), reducing BCAA synthesis, suppressing SHOC2-RAS-ERK signaling, and inducing apoptosis. Activity-based protein profiling (ABPP), pull-down Western blot, CETSA, microscale thermophoresis (MST) for EB–BCAT1 binding; HPLC metabolite quantification; SHOC2/RAS/ERK Western blot; in vivo mouse tumor model Journal of advanced research Medium 39490614
2024 NOTCH1 directly controls BCAT1 expression by binding to the BCAT1 promoter (ChIP validation). In a murine T-ALL model, Bcat1-deficient cells showed defects in developing leukemia. BCAT1 depletion in T-ALL cells redirected leucine metabolism toward production of 3-hydroxy butyrate (3-HB), an endogenous HDAC inhibitor, causing altered protein acetylation and sensitization to DNA-damaging agents. ChIP (NOTCH1 binding to BCAT1 promoter), Bcat1 genetic KO in murine T-ALL retroviral model, metabolomics (leucine to 3-HB pathway), protein acetylation analysis, etoposide sensitivity assay, patient-derived xenograft model Haematologica High 39234857
2024 In CD4+ T cells, BCAT1 generates β-hydroxy β-methylbutyric acid (HMB) as a metabolite from cytosolic leucine catabolism through BCAT1 and HPD/HPDL enzymes. HMB upregulates HIF1α mRNA, activating the mTORC1–HIF1α pathway and increasing IL-17 production in Th17 cells. BCAT1 inhibition (Bi2 or L-β-homoleucine) or silencing attenuates IL-17 production; HMB supplementation rescues this effect. In vivo, BCAT1 blockade mitigated EAE severity. shRNA and pharmacological (Bi2, L-β-homoleucine) BCAT1 inhibition, HMB supplementation rescue, mTORC1–HIF1α pathway analysis (Western blot, RT-PCR), IL-17 ELISA, in vivo EAE mouse model Experimental & molecular medicine Medium 39085353
1999 Overexpression of Bcat1/Eca39 in murine cells under serum deprivation leads to apoptotic cell death. The branched-chain keto acid α-ketoisocaproate (a product of BCAT1 leucine catabolism) can independently induce rapid apoptosis, suggesting BCAT1 promotes apoptosis via its metabolic products. Bcat1 overexpression in murine cells, cell viability assay under serum deprivation, α-ketoisocaproate treatment, apoptosis measurement FEBS letters Medium 10471790
2004 Exogenous BDNF upregulates BCATc (BCAT1) mRNA and protein in astrocytes of the rat dorsal lateral geniculate nucleus following visual cortex lesion, as identified by mRNA fingerprinting and confirmed by RT-PCR and in situ hybridization. This upregulation is cell-type specific (astrocytes rather than neurons in this lesion context), suggesting that BDNF-mediated neuroprotection involves modulation of glutamate metabolism by astrocytes via BCATc. mRNA fingerprinting, quantitative RT-PCR, in situ hybridization, immunohistochemistry in rat visual cortex lesion model with intraocular BDNF delivery The European journal of neuroscience Medium 15233768
2022 BCAT1 promotes osteoclast maturation through BCAA catabolism; enzymatic activity is required (enzymatically dead mutant abrogates maturation). BCAT1 loss or inhibition reduces mTORC1/S6K1 phosphorylation in osteoclast precursors, and ROS increase. mTORC1 stimulation rescues proliferation and reduces ROS in BCAT1 knockdown muscle cells, placing BCAT1 upstream of mTORC1–S6K1 signaling. shRNA-resistant BCAT1 cDNA rescue, enzymatically dead BCAT1 mutant, mTORC1/S6K1 phosphorylation by Western blot, ROS measurement, BCAT1 KD and mTORC1 activator (MYH1485) co-treatment in C2C12 muscle cells BMC musculoskeletal disorders Medium 35562710
2022 BCAT1 promotes AML by restricting αKG levels, leading to impaired αKG-dependent histone demethylase (KDM) activity, elevated H3K9me3, suppressed ATM expression, and impaired DNA damage repair. High BCAT1 AML cells have increased sensitivity to PARP inhibitors. BCAT1 KO/OE AML cell lines, αKG quantification, histone methylation (H3K9me3) by Western blot, ATM expression analysis, DNA damage assays, PARP inhibitor (BMN673) sensitivity in vivo and in vitro Journal of molecular medicine Medium 38340163
2024 BCAT1 in AML engages in bidirectional substrate reactions consuming BCAAs; BCAT1-driven leucine and αKG production activates mTOR (~2-fold higher p-S6K) in primary CLL cells with high BCAT1 expression. Disruption of BCAT1 in CLL-derived cell lines substantially reduces growth ex vivo. Steady-state metabolomics, heavy isotope metabolic tracing in primary CLL cells, p-S6K quantification by Western blot, BCAT1 disruption in cell lines Leukemia Medium 39455853
2025 In B cells, BCR/TLR9 costimulation highly induces BCAT1, which localizes to lysosomal membranes to support BCAA synthesis and mTORC1 activation. BCAT1 inhibition blunts BCR/TLR9-triggered (but not CD40L/IL-4-triggered) B cell proliferation, IL-10 expression, and lymphoma xenograft outgrowth. Transcriptomics, translatomics, and metabolomics of primary human B cells under distinct receptor stimuli; BCAT1 immunofluorescence localization to lysosomes; BCAT1 inhibition (pharmacological), BCR/TLR9 vs CD40L/IL-4 epistasis comparison; lymphoma xenograft model The Journal of clinical investigation High 40924473
2025 BCAT1 activity in Müller cells is negatively regulated by polo-like kinase 4 (Plk4)-mediated phosphorylation at threonine 333. In diabetic conditions, elevated BCAT1 activity in Müller cells reduces intracellular αKG levels, increases H3K4me3 at promoters of inflammatory genes (IL-6, TNF-α), and boosts retinal inflammation. BCAT1 inhibitors reduce inflammatory gene expression and vascular leakage in diabetic retinas in vivo. ChIP (H3K4me3 at inflammatory gene promoters), kinase screening (Plk4→BCAT1 phospho-Thr333), BCAT1 inhibitors (BAY-069, ERG240) in diabetic mouse models, targeted metabolomics (αKG measurement in Müller cells), RNA-seq Investigative ophthalmology & visual science Medium 40530920
2024 BCAT1 is directly regulated by P2X1-mediated signaling: ATP–P2X1 signaling upregulates PBX3, which transactivates BCAT1. P2X1 phosphorylation at S387 and T389 is required for its leukemia-promoting effects. P2X1 deletion impairs leukemia-initiating cell (LIC) self-renewal in AML, an effect mediated through the PBX3–BCAT1 pathway. P2X1 genetic deletion, P2X1 phospho-site mutants (S387A/T389A), ChIP/transactivation assay (PBX3 on BCAT1), AML mouse transplant model, human AML cell line knockdown Leukemia Medium 36418376
2024 BCAA/BCAT1 signaling enhances phosphorylation of CREB in TKI-resistant CML cells, which is required for maintenance of TKI-resistant leukemia. BCAT1 knockdown or BCAA deprivation abolishes CREB phosphorylation and leukemogenesis in a BCR-ABL T315I murine CML model. BCAT1 knockdown, BCAA stimulation in vitro, CREB phosphorylation by Western blot, BCR-ABLT315I murine transplant CML model, human TKI-resistant cell line proliferation assays Cellular oncology Medium 39412615
2024 Transcription factor EB (TFEB) directly regulates BCAT1 transcription to reprogram BCAA catabolism in pancreatic cancer cells. TFEB knockdown blocks BCAA catabolism by reducing BCAT1 expression, inhibiting proliferation and metastasis; combined BCAA deprivation and TFEB inhibition (eltrombopag) synergistically inhibits pancreatic cancer cell proliferation. TFEB knockdown (siRNA), BCAT1 mRNA/protein measurement, BCAA metabolomics, BCAA deprivation combined with eltrombopag treatment, proliferation and metastasis assays Cell proliferation Medium 38938061
2024 HuR RNA-binding protein directly interacts with BCAT1 mRNA, increasing its stability and translation, thereby upregulating BCAT1 protein and activating ERK5 signaling in castration-resistant prostate cancer. HuR KO or the HuR inhibitor KH-3 (which disrupts HuR–BCAT1 mRNA interaction) reduces BCAT1 expression and suppresses CRPC progression. HuR knockout (Cas9), mRNA half-life assay, RIP (HuR–BCAT1 mRNA), HuR inhibitor KH-3, ERK5 signaling by Western blot, xenograft tumor model Journal of translational medicine Medium 38369471
2019 miR-124-3p directly targets the BCAT1 mRNA 3'-UTR, resulting in BCAT1 upregulation when miR-124-3p is suppressed. DNMT1-mediated promoter hypermethylation silences miR-124-3p expression, establishing a DNMT1→miR-124-3p→BCAT1 axis that promotes ESCC proliferation and migration. miR-124-3p target validation (3'-UTR reporter/sequence analysis), DNMT1 knockdown and inhibition, miR-124-3p and BCAT1 expression in ESCC cell lines and tissues BMC cancer Medium 31226958
2021 BCAT1 activates the PI3K/AKT/mTOR pathway in gastric cancer cells, and pharmacological blockade with LY294002 reverses tumor growth induced by BCAT1 overexpression. BCAT1 promotes angiogenesis, invasion, and proliferation through this pathway. BCAT1 lentiviral overexpression/silencing, PI3K/AKT/mTOR pathway Western blot, LY294002 PI3K inhibitor rescue, xenograft model, angiogenesis assays Frontiers in cell and developmental biology Medium 34164393
2020 BCATc (BCAT1) knockdown in TNBC cells significantly reduced insulin- and IGF-1-mediated proliferation, migration, and invasion. BCATc overexpression regulates proliferation through the PI3K/Akt axis while simultaneously attenuating the Ras/ERK pathway, ultimately increasing FOXO3a and Nrf2. BCATc siRNA knockdown and overexpression, IGF-1/insulin stimulation, PI3K/Akt and Ras/ERK pathway Western blot, FOXO3a and Nrf2 protein levels, proliferation and invasion assays Oncotarget Medium 32523652

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2013 BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nature medicine 406 23793099
2017 BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature 308 29144447
2017 Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function. Biochemical and biophysical research communications 174 28235484
2020 Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours. Nature metabolism 169 32694827
2013 Over-expression of BCAT1, a c-Myc target gene, induces cell proliferation, migration and invasion in nasopharyngeal carcinoma. Molecular cancer 128 23758864
2015 Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia. BMC cancer 104 26445409
2015 BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism. Oncotarget 92 26372729
2016 A Blood Test for Methylated BCAT1 and IKZF1 vs. a Fecal Immunochemical Test for Detection of Colorectal Neoplasia. Clinical and translational gastroenterology 89 26765125
2016 A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer. Cancer medicine 82 27726312
2014 Cytosolic branched chain aminotransferase (BCATc) regulates mTORC1 signaling and glycolytic metabolism in CD4+ T cells. The Journal of biological chemistry 81 24847056
2021 BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism. Cell death & disease 80 33568627
2004 Branched-chain amino acids and neurotransmitter metabolism: expression of cytosolic branched-chain aminotransferase (BCATc) in the cerebellum and hippocampus. The Journal of comparative neurology 74 15329886
2023 Enhanced BCAT1 activity and BCAA metabolism promotes RhoC activity in cancer progression. Nature metabolism 70 37337119
2021 BCAT1 Activates PI3K/AKT/mTOR Pathway and Contributes to the Angiogenesis and Tumorigenicity of Gastric Cancer. Frontiers in cell and developmental biology 54 34164393
2016 DOT1L histone methyltransferase regulates the expression of BCAT1 and is involved in sphere formation and cell migration of breast cancer cell lines. Biochimie 48 26783998
2018 LncRNA CRNDE promotes hepatocellular carcinoma cell proliferation, invasion, and migration through regulating miR-203/ BCAT1 axis. Journal of cellular physiology 47 30230527
1999 Involvement of branched-chain amino acid aminotransferase (Bcat1/Eca39) in apoptosis. FEBS letters 46 10471790
2022 Targeting BCAT1 Combined with α-Ketoglutarate Triggers Metabolic Synthetic Lethality in Glioblastoma. Cancer research 45 35499760
2019 The role of DNMT1/hsa-miR-124-3p/BCAT1 pathway in regulating growth and invasion of esophageal squamous cell carcinoma. BMC cancer 42 31226958
2022 BCAT1 promotes osteoclast maturation by regulating branched-chain amino acid metabolism. Experimental & molecular medicine 39 35760874
2016 BCAT1 promotes tumor cell migration and invasion in hepatocellular carcinoma. Oncology letters 39 27698837
2002 Structure, function and regulation of the cyanobacterial high-affinity bicarbonate transporter, BCT1. Functional plant biology : FPB 37 32689462
2021 Proteomic analysis of lung cancer cells reveals a critical role of BCAT1 in cancer cell metastasis. Theranostics 36 34646394
2017 MicroRNA-218 inhibits tumor growth and increases chemosensitivity to CDDP treatment by targeting BCAT1 in prostate cancer. Molecular carcinogenesis 34 28052414
2022 Ruscogenin Alleviates Myocardial Ischemia-Induced Ferroptosis through the Activation of BCAT1/BCAT2. Antioxidants (Basel, Switzerland) 33 35326233
2022 Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1. Molecular oncology 31 35000264
2022 BCAT1 redox function maintains mitotic fidelity. Cell reports 30 36260995
2020 Evaluation of Circulating Tumor DNA for Methylated BCAT1 and IKZF1 to Detect Recurrence of Stage II/Stage III Colorectal Cancer (CRC). Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 30 32958500
2018 BCAT1 promotes proliferation of endometrial cancer cells through reprogrammed BCAA metabolism. International journal of clinical and experimental pathology 30 31949641
2021 Oxoeicosanoid receptor inhibition alleviates acute myocardial infarction through activation of BCAT1. Basic research in cardiology 29 33484341
2020 BCAT1 Overexpression Promotes Proliferation, Invasion, and Wnt Signaling in Non-Small Cell Lung Cancers. OncoTargets and therapy 29 32425554
2024 Inhibition of BCAT1-mediated cytosolic leucine metabolism regulates Th17 responses via the mTORC1-HIF1α pathway. Experimental & molecular medicine 28 39085353
2021 Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer. Clinical epigenetics 27 33478584
2022 BCAT1: A risk factor in multiple cancers based on a pan-cancer analysis. Cancer medicine 25 34984849
2007 Functional evidence for a nasopharyngeal carcinoma-related gene BCAT1 located at 12p12. Oncology research 23 18074675
2024 BCAT1 alleviates early brain injury by inhibiting ferroptosis through PI3K/AKT/mTOR/GPX4 pathway after subarachnoid hemorrhage. Free radical biology & medicine 22 38871197
2020 BCAT1 binds the RNA-binding protein ZNF423 to activate autophagy via the IRE1-XBP-1-RIDD axis in hypoxic PASMCs. Cell death & disease 22 32938905
2018 Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study. PloS one 22 30265706
2021 BCAT1 overexpression regulates proliferation and c‑Myc/GLUT1 signaling in head and neck squamous cell carcinoma. Oncology reports 20 33760210
2022 The BCAT1 CXXC Motif Provides Protection against ROS in Acute Myeloid Leukaemia Cells. Antioxidants (Basel, Switzerland) 19 35453368
2021 Flotillin-2 promotes cell proliferation via activating the c-Myc/BCAT1 axis by suppressing miR-33b-5p in nasopharyngeal carcinoma. Aging 19 33744853
2020 BCATc modulates crosstalk between the PI3K/Akt and the Ras/ERK pathway regulating proliferation in triple negative breast cancer. Oncotarget 19 32523652
2020 Silencing of Long Noncoding RNA LINC00324 Interacts with MicroRNA-3200-5p to Attenuate the Tumorigenesis of Gastric Cancer via Regulating BCAT1. Gastroenterology research and practice 19 32855634
2024 Small-molecule targeting BCAT1-mediated BCAA metabolism inhibits the activation of SHOC2-RAS-ERK to induce apoptosis of Triple-negative breast cancer cells. Journal of advanced research 18 39490614
2021 BCAT1 knockdown-mediated suppression of melanoma cell proliferation and migration is associated with reduced oxidative phosphorylation. American journal of cancer research 18 34249421
2023 The emerging role of the branched chain aminotransferases, BCATc and BCATm, for anti-tumor T-cell immunity. Immunometabolism (Cobham, Surrey) 17 36644500
2022 BCATc inhibitor 2 ameliorated mitochondrial dysfunction and apoptosis in oleic acid-induced non-alcoholic fatty liver disease model. Frontiers in pharmacology 17 36386234
2020 USF1-mediated upregulation of lncRNA GAS6-AS2 facilitates osteosarcoma progression through miR-934/BCAT1 axis. Aging 17 32269179
2020 LINC00963 Confers Oncogenic Properties in Glioma by Regulating the miR-506/BCAT1 Axis. Cancer management and research 17 32273770
2021 Long non-coding RNA TMPO-AS1 facilitates the progression of colorectal cancer cells via sponging miR-98-5p to upregulate BCAT1 expression. Journal of gastroenterology and hepatology 16 34370878
2018 Gabapentin Can Suppress Cell Proliferation Independent of the Cytosolic Branched-Chain Amino Acid Transferase 1 (BCAT1). Biochemistry 16 30427175
2022 Detection of hypermethylated BCAT1 and IKZF1 DNA in blood and tissues of colorectal, breast and prostate cancer patients. Cancer biomarkers : section A of Disease markers 15 35253733
2022 Detection of recurrent colorectal cancer with high specificity using a reporting threshold for circulating tumor DNA methylated in BCAT1 and IKZF1. Cancer 15 35290664
2022 Impaired expression of BCAT1 relates to muscle atrophy of mouse model of sarcopenia. BMC musculoskeletal disorders 15 35562710
2021 Curcumin induces apoptosis by inhibiting BCAT1 expression and mTOR signaling in cytarabine‑resistant myeloid leukemia cells. Molecular medicine reports 15 34109436
2019 Data mining of the expression and regulatory role of BCAT1 in hepatocellular carcinoma. Oncology letters 15 31788061
2017 Reciprocal control of lncRNA-BCAT1 and β-catenin pathway reveals lncRNA-BCAT1 long non-coding RNA acts as a tumor suppressor in colorectal cancer. Oncotarget 15 28416735
2024 Cross-talk between BCKDK-mediated phosphorylation and STUB1-dependent ubiquitination degradation of BCAT1 promotes GBM progression. Cancer letters 14 38621458
2021 Mutant IDH1 inhibitors activate pSTAT3-Y705 leading to an increase in BCAT1 and YKL-40 levels in mutant IDH1-expressing cells. Biochimica et biophysica acta. Molecular cell research 14 34329662
2004 Intraocular delivery of BDNF following visual cortex lesion upregulates cytosolic branched chain aminotransferase (BCATc) in the rat dorsal lateral geniculate nucleus. The European journal of neuroscience 14 15233768
2022 Identification of natural compounds tubercidin and lycorine HCl against small-cell lung cancer and BCAT1 as a therapeutic target. Journal of cellular and molecular medicine 13 35318805
2022 Circular RNA VPS18 Promotes Glioblastoma Progression by Regulating miR-1229-3p/BCAT1 Axis. Neurotoxicity research 13 35776379
2017 Validation of a Circulating Tumor-Derived DNA Blood Test for Detection of Methylated BCAT1 and IKZF1 DNA. The journal of applied laboratory medicine 13 32630973
2016 Assessment of bevacizumab resistance increased by expression of BCAT1 in IDH1 wild-type glioblastoma: application of DSC perfusion MR imaging. Oncotarget 13 27626306
2024 Transcription factor EB reprograms branched-chain amino acid metabolism and promotes pancreatic cancer progression via transcriptional regulation of BCAT1. Cell proliferation 12 38938061
2022 BCAT1 promotes lung adenocarcinoma progression through enhanced mitochondrial function and NF-κB pathway activation. Journal of Zhejiang University. Science. B 12 36111572
2022 P2X1 enhances leukemogenesis through PBX3-BCAT1 pathways. Leukemia 12 36418376
2003 Lrmp and Bcat1 are candidates for the type I diabetes susceptibility locus Idd6. Autoimmunity 12 14563018
2024 BCAT1, IKZF1 and SEPT9: methylated DNA biomarkers for detection of pan-gastrointestinal adenocarcinomas. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 11 38644767
2019 Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma. Neurosurgery 11 30113684
2006 Expression of cytosolic branched chain aminotransferase (BCATc) mRNA in the developing mouse brain. Gene expression patterns : GEP 11 17150414
2024 Engineering the cyanobacterial ATP-driven BCT1 bicarbonate transporter for functional targeting to C3 plant chloroplasts. Journal of experimental botany 10 38776254
2023 LncRNA THUMPD3-AS1 promotes invasion and EMT in gastric cancer by regulating the miR-1297/BCAT1 pathway. iScience 10 37705956
2022 Translation of a tissue epigenetic signature to circulating free DNA suggests BCAT1 as a potential noninvasive diagnostic biomarker for lung cancer. Clinical epigenetics 10 36123616
2018 BCAT1 and miR-2504: novel methylome signature distinguishes spindle/desmoplastic melanoma from superficial malignant peripheral nerve sheath tumor. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 10 30310175
2006 Cytosolic branched chain aminotransferase (BCATc) mRNA is up-regulated in restricted brain areas of BDNF transgenic mice. Brain research 10 16828066
2025 BCAT1 is a NOTCH1 target and sustains the oncogenic function of NOTCH1. Haematologica 8 39234857
2022 The proatherosclerotic function of BCAT1 in atherosclerosis development of aged-apolipoprotein E-deficient mice. Biochemical and biophysical research communications 8 36182869
2018 [The Expression and Significance of c-myc and bcat1 in Cervical Cancer]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 8 30378334
2025 SIRT5-mediated BCAT1 desuccinylation and stabilization leads to ferroptosis insensitivity and promotes cell proliferation in glioma. Cell death & disease 7 40195331
2023 LncRNA PSMB8-AS1 increases glioma malignancy via the miR-382-3p/BCAT1 axis. Translational oncology 7 38235619
2025 BCAT1 Activation Reprograms Branched-Chain Amino Acid Metabolism and Epigenetically Promotes Inflammation in Diabetic Retinopathy. Investigative ophthalmology & visual science 6 40530920
2024 High expression of BCAT1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage response. Journal of molecular medicine (Berlin, Germany) 6 38340163
2024 BCAT1 contributes to the development of TKI-resistant CML. Cellular oncology (Dordrecht, Netherlands) 6 39412615
2024 Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia. Leukemia 6 39455853
2023 BCAT1 controls embryonic neural stem cells proliferation and differentiation in the upper layer neurons. Molecular brain 6 37344908
2021 Variables Associated with Detection of Methylated BCAT1 or IKZF1 in Blood from Patients Without Colonoscopically Evident Colorectal Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 6 33500319
2024 HuR promotes castration-resistant prostate cancer progression by altering ERK5 activation via posttranscriptional regulation of BCAT1. Journal of translational medicine 5 38369471
2024 CHIP-mediated ubiquitin degradation of BCAT1 regulates glioma cell proliferation and temozolomide sensitivity. Cell death & disease 5 39075053
2024 Inhibition of BCAT1 expression improves recurrent miscarriage by regulating cellular dysfunction and inflammation of trophoblasts. Cell and tissue research 5 39356334
2024 BCAT1 promotes cell proliferation, migration, and invasion via the PI3K-Akt signaling pathway in oral squamous cell carcinoma. Oral diseases 4 39056279
2024 Identify BCAT1 plays an oncogenic role and promotes EMT in KIRC via single cell RNA-seq and experiment. Frontiers in oncology 4 39324007
2022 Driving with Both Feet: Supplementing AKG While Inhibiting BCAT1 Leads to Synthetic Lethality in GBM. Cancer research 4 35788291
2019 BCAT1 and BCAT2 disruption in CHO cells has cell line-dependent effects. Journal of biotechnology 4 31465797
2018 Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature 4 30069041
2025 Design, Synthesis and Biological Activity Study of γ-Aminobutyric Acid (GABA) Derivatives Containing Bridged Bicyclic Skeletons as BCAT1 Inhibitors. Molecules (Basel, Switzerland) 3 40005214
2023 MiR-320a Acts as a Tumor Suppressor in Somatotroph Pituitary Neuroendocrine Tumors by Targeting BCAT1. Neuroendocrinology 3 37591221
2023 Knockdown of PRMT1 suppresses the malignant biological behavior of osteosarcoma cells and increases cisplatin sensitivity via c-Myc-mediated BCAT1 downregulation. Journal of biochemical and molecular toxicology 3 37700640
2025 Multiomic analysis reveals a key BCAT1 role in mTOR activation by B cell receptor and TLR9. The Journal of clinical investigation 2 40924473
2024 A blood test measuring DNA methylation of BCAT1 and IKZF1 for detection of lung adenocarcinoma. Cancer treatment and research communications 2 39154541

Missed literature

Know a paper Affinage missed for BCAT1? Flag it for the maintainers and the community.

No submissions yet.